| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
| Targets |
4-Hydroxyphenylboronic acid pinacol ester has been shown to bind to hepcidin, a peptide hormone that regulates iron homeostasis. It has been shown to be active in the treatment of anemic patients with chronic kidney disease. It has ROS-responsive properties and can be used to construct intelligent drug delivery systems.
|
|---|---|
| ln Vitro |
In vitro, 4-hydroxyphenylboronic acid pinacol ester is used as a biochemical reagent and synthetic intermediate. It is widely used in Suzuki coupling chemistry, a type of palladium-catalyzed cross-coupling reaction. Its ROS-responsive properties allow it to modify hyaluronic acid to construct intelligent drug delivery systems, enabling specific release of drugs in ROS environments.
|
| ln Vivo |
In vivo data for 4-hydroxyphenylboronic acid pinacol ester as a therapeutic agent are limited. It has been shown to be active in the treatment of anemic patients with chronic kidney disease. Its ability to bind hepcidin suggests potential for in vivo studies in iron homeostasis and anemia.
|
| Enzyme Assay |
For in vitro chemical synthesis, 4-hydroxyphenylboronic acid pinacol ester is used as a reagent in Suzuki-Miyaura cross-coupling reactions. Standard protocols involve reacting the boronic ester with an aryl halide in the presence of a palladium catalyst and a base in an appropriate solvent. The pinacol ester can be hydrolyzed to the boronic acid for further reactions.
|
| Cell Assay |
For in vitro cell-based experiments, 4-hydroxyphenylboronic acid pinacol ester is used as a building block or reagent. It may be used to synthesize compounds that are subsequently tested in cell-based assays. Its ROS-responsive properties make it a candidate for studying drug delivery systems in cell culture models of oxidative stress.
|
| Animal Protocol |
In vivo animal studies using 4-hydroxyphenylboronic acid pinacol ester are limited. For potential therapeutic candidates derived from this compound, efficacy studies would typically be performed in mouse models of anemia or chronic kidney disease. Standard in vivo protocols involve administration to rodents via oral gavage or intravenous injection.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4-hydroxyphenylboronic acid pinacol ester as a standalone compound are not characterized in the literature. The compound has a molecular weight of 220.1 g/mol, which is favorable for oral bioavailability. The pinacol ester may be hydrolyzed in vivo to the active boronic acid.
|
| Toxicity/Toxicokinetics |
4-Hydroxyphenylboronic acid pinacol ester is a research chemical and should be handled with appropriate laboratory safety precautions. As a boronic ester, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications.
|
| Additional Infomation |
4-Hydroxyphenylboronic acid pinacol ester (CAS 269409-70-3) is primarily a research-grade chemical intermediate and biochemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are as a reagent in Suzuki coupling chemistry, as a ROS-responsive material for drug delivery, and as a potential agent for anemia research.
|
| Molecular Formula |
C12H17BO3
|
|---|---|
| Molecular Weight |
220.07
|
| Exact Mass |
220.127
|
| CAS # |
269409-70-3
|
| PubChem CID |
2734624
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
333.8±25.0 °C at 760 mmHg
|
| Melting Point |
113-117 °C(lit.)
|
| Flash Point |
155.7±23.2 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.515
|
| LogP |
1.691
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
16
|
| Complexity |
241
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1(C)C(C)(C)OB(C2=CC=C(C=C2)O)O1
|
| InChi Key |
BICZJRAGTCRORZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H17BO3/c1-11(2)12(3,4)16-13(15-11)9-5-7-10(14)8-6-9/h5-8,14H,1-4H3
|
| Chemical Name |
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (454.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5440 mL | 22.7200 mL | 45.4401 mL | |
| 5 mM | 0.9088 mL | 4.5440 mL | 9.0880 mL | |
| 10 mM | 0.4544 mL | 2.2720 mL | 4.5440 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
